Cencora, Inc. (NYSE:COR) Shares Sold by KBC Group NV

KBC Group NV trimmed its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 2.1% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 321,970 shares of the company's stock after selling 7,065 shares during the period. KBC Group NV owned 0.17% of Cencora worth $89,537,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Hoey Investments Inc. purchased a new position in shares of Cencora in the 1st quarter valued at approximately $28,000. Banque Transatlantique SA acquired a new stake in shares of Cencora during the fourth quarter worth $29,000. SBI Securities Co. Ltd. purchased a new position in Cencora in the 4th quarter valued at $30,000. Vermillion Wealth Management Inc. acquired a new position in Cencora in the 4th quarter valued at $38,000. Finally, OFI Invest Asset Management purchased a new position in Cencora during the 4th quarter worth $41,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Citigroup lifted their target price on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. UBS Group lifted their price objective on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Robert W. Baird boosted their target price on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Jefferies Financial Group lifted their price target on Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a research note on Monday. Finally, Bank of America upped their price objective on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $306.33.

Cencora Price Performance

NYSE COR traded down $4.26 during trading hours on Wednesday, reaching $291.07. The company's stock had a trading volume of 1,205,767 shares, compared to its average volume of 1,503,964. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87. The company's 50-day moving average is $290.50 and its two-hundred day moving average is $266.13. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35. The stock has a market cap of $56.41 billion, a PE ratio of 33.77, a PEG ratio of 1.49 and a beta of 0.57.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The business had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same period in the prior year, the business earned $3.80 earnings per share. The company's quarterly revenue was up 10.3% on a year-over-year basis. Analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.76%. Cencora's dividend payout ratio (DPR) is 25.52%.

Insider Buying and Selling at Cencora

In related news, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer owned 47,582 shares of the company's stock, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the sale, the chairman directly owned 311,913 shares in the company, valued at $91,271,982.06. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,127 shares of company stock worth $9,812,296 over the last 90 days. Company insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.